Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
| Status: | Terminated |
|---|---|
| Conditions: | Colorectal Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/12/2017 |
| Start Date: | September 2003 |
| End Date: | January 2012 |
Phase I Trial Of Adenoviral Vector Delivery Of The Human Interleukin-12 cDNA By Intratumoral Injection In Patients With Metastatic Colorectal Cancer To The Liver
RATIONALE: Inserting the interleukin-12 gene into a person's cancer cells may make the body
build an immune response to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12
gene when injected into the tumors of patients with liver metastases secondary to colorectal
cancer.
build an immune response to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of interleukin-12
gene when injected into the tumors of patients with liver metastases secondary to colorectal
cancer.
OBJECTIVES:
- Determine the toxicity and maximum tolerated dose of intratumoral adenoviral
vector-delivered interleukin-12 gene in patients with liver metastases secondary to
colorectal cancer .
- Determine the tumor response in patients treated with this regimen.
- Determine the immune response in patients treated with this regimen.
- Determine the toxicity and maximum tolerated dose of intratumoral adenoviral
vector-delivered interleukin-12 gene in patients with liver metastases secondary to
colorectal cancer .
- Determine the tumor response in patients treated with this regimen.
- Determine the immune response in patients treated with this regimen.
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed* colorectal adenocarcinoma metastatic to
the liver
- Solitary or multiple metastatic tumors in the liver
- Metastatic involvement of the liver no greater than 40% of estimated liver
volume NOTE: *Must be from the hepatic tumor designated for study injection
- Metastatic liver tumors must be bidimensionally measurable by CT scan or MRI
- At least 1 metastatic liver tumor measuring at least 2.0 cm must be visualized by
ultrasound (US) and accessible for US-guided percutaneous injection
- Extrahepatic metastases allowed
- No prior or current ascites
- Ineligible for hepatic resection
PATIENT CHARACTERISTICS:
Age
- Adult
Performance status
- Karnofsky 70-100%
Life expectancy
- At least 16 weeks
Hematopoietic
- Granulocyte count at least 1,500/mm^3
- Hemoglobin at least 9.0 g/dL
- Platelet count at least 100,000/mm^3
Hepatic
- No clinical evidence of other severe liver disease (e.g., portosystemic
encephalopathy)
- PT no greater than 14 seconds
- Bilirubin no greater than 2.0 times upper limit of normal (ULN)
- Transaminases no greater than 2.5 times ULN
Renal
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance at least 45 mL/min
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective nonhormonal contraception during and for at least
2 months after study participation
- HIV negative
- No active infection
- No other concurrent serious medical illness
- No other malignancy within the past 5 years except inactive nonmelanoma skin cancer,
carcinoma in situ of the cervix, or grade 1 papillary bladder cancer
- Oriented and rational
- Weight at least 30 kg
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
Endocrine therapy
- At least 2 months since prior corticosteroids
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- At least 2 months since prior systemic immunosuppressive drugs
- No concurrent immunosuppressive drugs
- No concurrent anticoagulant therapy with heparin or warfarin
We found this trial at
1
site
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
Click here to add this to my saved trials
